LINCOLN, Neb.--(BUSINESS WIRE)--LI-COR Biosciences has entered into a licensing agreement with The Johns Hopkins University (Baltimore, MD) for compounds and imaging methods targeting prostate-specific membrane antigen (PSMA) developed in the laboratory of Dr. Martin Pomper. As an enzyme with an extracellular active site, PSMA represents an excellent target for imaging and therapy directed toward solid tumor neovasculature in addition to prostate cancer itself.
